Scottish Medicines Consortium Accepts Bronchitol For Use In Cystic Fibrosis Patients

Link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland.  Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of […]

19.09.2013 – Pharmaxis Announces Two Board Retirements

Pharmaxis announcement link here. Pharmaceutical company Pharmaxis today announced the retirement of two non‐executive directors, Dr John Villiger and Mr Richard van den Broek. Dr Villiger joined the Board in November 2006. His career in the global pharmaceutical industry as a founder of The Medicines Company Inc. brought considerable clinical, regulatory and entrepreneurial experience to the […]

Pharmaxis Announces Delay to French Pricing for Bronchitol

Pharmaxis press release link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for the cystic fibrosis treatment. Pharmaxis CEO Mr Gary Phillips said, “Negotiations with the French Healthcare […]

Australian Medical Media Release: Simplified PBS Listing for Bronchitol (Pharmaxis)

Pharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]